CHS/Pfizer Care until Cure Research Program
CHS/Pfizer Care until Cure Research Program supports Canadian investigators studying medical and psychosocial aspects of bleeding disorders to improve quality of life for people affected by them.
Funder: Bleeding Disorders Canada (formerly Canadian Hemophilia Society)
Due Dates: November 27, 2026 (Application deadline)
Funding Amounts: Up to $75,000 per year per project, maximum $150,000 over 2 or 3 years
Summary: Supports Canadian investigators researching medical and psychosocial aspects of bleeding disorders to improve quality of life.
Key Information: Applicants must be Canadian citizens or permanent residents affiliated with a Canadian university or not-for-profit health-related organization.
Description
Bleeding Disorders Canada administers this research program in collaboration with Pfizer Canada. Established in 2000 with Wyeth Canada, now Pfizer, it supports research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Its goal is to improve quality of life for people with hemophilia, von Willebrand disease and other inherited bleeding disorders, carriers, and people with related conditions such as HIV or hepatitis C.
The program identifies interests in disease burden, real-world data, patient-reported outcomes, personalized treatment, clinical monitoring, gene therapy, tissue factor pathway inhibitor (TFPI) biology and antifibrinolytic therapy. These interests are not exhaustive: the grants review committee directs funding to the strongest and most relevant projects. The Canadian Hemophilia Society became Bleeding Disorders Canada in July 2026, so application documents may use either name.
